Bank of Montreal Can purchased a new stake in MediciNova, Inc. (NASDAQ:MNOV – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 127,300 shares of the biopharmaceutical company’s stock, valued at approximately $311,000. Bank of Montreal Can owned about 0.26% of MediciNova as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich lifted its holdings in MediciNova by 98,059.1% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 18,650,237 shares of the biopharmaceutical company’s stock worth $42,896,000 after buying an additional 18,631,237 shares during the last quarter. Geode Capital Management LLC raised its position in shares of MediciNova by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 437,247 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 4,374 shares during the period. JPMorgan Chase & Co. raised its position in shares of MediciNova by 2.4% during the 1st quarter. JPMorgan Chase & Co. now owns 308,276 shares of the biopharmaceutical company’s stock worth $823,000 after purchasing an additional 7,110 shares during the period. Jane Street Group LLC acquired a new stake in shares of MediciNova during the 4th quarter worth approximately $549,000. Finally, Bank of America Corp DE raised its position in shares of MediciNova by 14.5% during the 4th quarter. Bank of America Corp DE now owns 177,259 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 22,508 shares during the period. Hedge funds and other institutional investors own 10.97% of the company’s stock.
MediciNova Price Performance
MNOV opened at $2.06 on Tuesday. MediciNova, Inc. has a 12 month low of $1.71 and a 12 month high of $2.73. The stock has a market cap of $101.04 million, a P/E ratio of -10.84 and a beta of 0.91. The stock’s 50 day moving average price is $1.98 and its 200 day moving average price is $2.19.
Analysts Set New Price Targets
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
- Five stocks we like better than MediciNova
- Crypto vs Stocks: How to Choose Your Investments
- The most upgraded stocks in November have two things in common
- Business Services Stocks Investing
- Monday.com rocked earnings like it’s the weekend
- Stock Splits, Do They Really Impact Investors?
- Plan to own one retailer? Make it this one
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.